Funding Opportunities

The NCI Division of Cancer Prevention funds new research in cancer prevention, detection, screening, interception, and symptom management. We also fund programs to train people for careers in research. Explore current open funding opportunities here and streamline your search by using keyword or type of funding.

Information about the funding opportunity announcements that align with the efforts of the Cancer MoonshotSM can be found here: https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/funding.
 

Notice of Funding Opportunities

Title Announcement Number Activity Code Clinical Trials Status Expiration Date Program Official
Patient-Clinician Relationship: Improving Health Outcomes in Populations that Experience Health Care Disparities PAR-22-064 (R01 Clinical Trial Optional) R01 Clinical Trial Optional 01/08/2025
Notice of Intent to Publish a Funding Opportunity Announcement for Consortium for Palliative Care Research Across the Lifespan NOT-AG-23-050 (U54 Clinical Trial Required) U54 Clinical Trial Required 12/31/2024 Brennan Streck, Ph.D., R.N., M.P.H.
HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment RFA-NS-22-034 (R01 Clinical Trial Not Allowed) R01 Clinical Trial Not Allowed 12/07/2024 Rachel Altshuler, Ph.D.
Notice of Special Interest (NOSI): Career Development Opportunities for Research Within the Mission of the Division of Cancer Prevention at the National Cancer Institute NOT-CA-23-035 11/13/2024 Jessica Faupel-Badger, Ph.D., M.P.H.
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies PAR-21-329 (R01 Clinical Trial Optional) R01 Clinical Trial Optional 11/06/2024
Notice of Special Interest (NOSI): Improving Outcomes in Cancer Treatment-Related Cardiotoxicity NOT-CA-22-001 11/06/2024
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research PAR-21-330 (U01 Clinical Trial Not Allowed) U01 Clinical Trial Not Allowed 10/12/2024 Claire Zhu, Ph.D.
Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research RFA-CA-24-013 (U01 Clinical Trial Optional) U01 Clinical Trial Optional 10/02/2024 Guillermo Marquez, Ph.D.
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research RFA-CA-24-014 (P50 Clinical Trial Optional) P50 Clinical Trial Optional 10/02/2024 Guillermo Marquez, Ph.D.
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research RFA-CA-24-012 (R01 Clinical Trial Optional) R01 Clinical Trial Optional 10/02/2024 Guillermo Marquez, Ph.D.